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Abstract 
Glioblastoma multiforme (GBM), a high-grade, malignant brain tumor of 
astrocyte origin, invades normal brain tissue and most often results in death of the patient 
within a year of diagnosis. In order to invade the surrounding tissue and thereby 
metastasize, these tumor cells must migrate through the extracellular matrix. The 
pmpose of this research project is to investigate the family of matrix metalloproteinases 
responsible for extracellular degradation. Specifically, this investigation looks at MMP-2 
activation via MT 1-MMP and the possible importance of phosphorylation of the tyrosine 
residue on the cytoplasmic tail of MTl-MMP. U87 wild type glioma cells as well as T98 
p53 mutant glioma cells were treated with transforming growth factor beta (TGF-P). 
P reliminary results indicate a lesser concentration ofMTl-MMP and a greater 
concentration of phosphorylated tyrosine (P-Tyr) in the treated U87 cells. Similar 
experiments with T98 cells indicate a lesser concentration of MTl-MMP in the treated 
samples and no effect on the phosphorylation of tyrosine. Results with TGF-P-treated 
T98 cells imply that TGF-P does not upregulate MTl-MMP production. U87 cells were 
also treated with epidermal growth factor (EGF). Results indicate a greater concentration 
ofMTl-MMP as well as a greater concentration of phosphorylated tyrosine in the EGF­
treated conditions. Zymography results shows no effect ofEGF treatment on MMP-2 
production. While TGF-P has not been found to upregulate MTl-MMP production in 
either U87 or T98 cells, results do indicate that EGF upregulates MTl-MMP as well as 
phosphorylation of the tyrosine residue in U87 cells. 
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Introduction 
Gliomas originate from glial cells in the brain and are among many tumors which 
arise from an imbalance in cell proliferation and cell death. Frequently referred to as 
astrocytomas, gliomas often originate from astrocytes. In the United States alone, nearly 
twenty-five thousand new cases of gliomas surface annually, making gliomas the most 
common primary tumor of the brain (Furuta et al., 2004). Gliomas can occur in the 
cerebellum, causing such symptoms as headache, vomiting and unsteadiness in walking. 
Gliomas also occur in the posterior cerebral hemisphere, often causing seizures 
(Zimmerman et al., 1956). Gliomas, or astrocytomas, are divided into two main types: 
low-grade and high-grade. In contrast to localized, low-grade gliomas which are 
characterized by slow growth, high-grade tumors are characterized by aggressive, rapid 
growth and require intensive therapy. The two most common high-grade gliomas are 
Anaplastic Astrocytoma (AA-grade III) and Glioblastorna Multiforme (GBM-grade IV). 
As a high-grade, malignant brain tumor, GBM has an incredible ability to invade the 
surrounding nonnal brain tissue. GBM often causes infiltrated cells to escape detection 
and avoid surgical resection, eventually leading to tumor recurrence in another part of the 
brain. Although patients diagnosed with high-grade astrocytomas commonly receive 
both radiation and chemotherapy, prognosis is poor. Fewer than 5% of patients with 
GBM treated with aggressive therapy for a year survive for five years (Furuta et al. 
2004). Furthermore, most patients die within a year of diagnosis (Furuta et al. 2004). 
One major objective of research involving gliomas is to understand how these tumor cells 
migrate in order to develop anticancer therapy. 
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In order for cancer cells to metastasize, they must migrate through the 
extracellular matrix (ECM). Extracellular matrices contribute to tissue architecture, with 
extracellular matrices components regulating and influencing such processes as cell 
growth, differentiation and adhesion. The extracellular matrix in the brain includes such 
components as tenascin, neurocan, and hyaluronan. Matrix metalloproteinases (MMPs) 
have been implicated in the proteolytic cascades resulting in ECM degradation, and thus 
are an important point of study in tumor cell migration. Research has shown that MMPs 
are upregulated in almost all types of human cancer, and that their expression is often 
indicative of poor survival due to an increase in the invasive and metastatic potential of 
the tumor (Egeblad and Werb, 2002). 
The MMP family is made up of nearly thirty enzymes which are all Zn2+­
dependent endopeptidases (Chang and Werb, 2001). These enzymes are broken up into 
eight structural classes: simple hemopexin domain, gelatin-binding minimal domain, 
furin-activated and secreted, transmembrane, GPI-linked, vitronectin-like insert and Type 
II transmembrane. MMPs are initially secreted in an inactive form as proenzymes, and 
are later activated to create the mature MMP enzyme. MMPs play a large role in the 
regulation of tumor microenvironments and regulate ce11 behaviors pertinent to cancer 
cell biology such as growth, differentiation, apoptosis, invasion and migration (Egeblad 
and Werb, 2002). One such noteworthy MMP enzyme, MMP-2, has been positively 
correlated with glioma cell invasion (Ubm et al., 1997). MMP-2 is synthesized by tumor 
stromal cells such as inflammatory cells, fibroblasts myofibroblasts and endothelial cells. 
Like other MMPs, MMP-2 is initially secreted in its proenzyme form referred to as 
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proMMP-2 with a length of 68kDa. This proMMP-2 molecule is activated by a cleavage 
complex into its active MMP-2 form at 62kDa. 
One specific group ofMMPs referred to as MT-MMPs is unique in that each MT­
MMP contains a short cytoplasmic tail and a hydrophobic transmembrane domain at the 
C-terrninus which dictates localization to the cell surface (Gingras et al., 2000). One
such MT-MMP family member is a 63kDa, membrane-anchored enzyme called MTl­
MMP. MTl-MMP makes up part of the cleavage complex responsible for activation of 
MMP-2. Specific research on MTl-MMP has indicated that its cytoplasmic domain 
plays an important role in cell invasion by controlling the cell's targeting and degradation 
processes (Lehti et al., 1999). It has also been shown that there are three possible 
phosphorylation sites on the cytoplasmic tail ofMTl -MMP: Serine577, Tyrosine573 and 
Threonine567 (Lehti et al., 2000). This project investigates the possibility that regulation 
of MTl-MMP may be the result of phosphorylation of tyrosine on its cytoplasmic tail. 
Additionally, considerable evidence has demonstrated that tissue inhjbitor of 
metalloproteinases (TIMPs) are also involved in promoting tumor activity. For example, 
a positive correlation between tissue levels of TIMP-1 and more invasive stages of cancer 
has been found in colon cancer cells (Blavier et al., 1999). Another TIMP molecule, 
TIMP-2, serves as an adaptor molecule regulating proMMP-2 activation. TIMP-2 ha 
also been correlated with an increase in tyrosine phosphorylation of proteins as it 
stimulates adenylate cyclase and cyclic AMP-dependent activation of protein kinase A 
(Blavier et al., 1999). TIMP-2 is part of a cleavage complex formed between one MTl ­
MMP enzyme and one TIMP-2 molecule which can be cleaved by an adjacent MTl-
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MMP molecule, ultimately resulting in a trimolecular complex. It is this membrane­
bound, trimolecular complex which is responsible for MMP-2 activation outside the cell. 
Upregulat:ion of proMMP-2 production occurs through various signal transduction 
pathways activated by exogenous growth factors. Growth factors bind to transmembrane 
cell receptors, subsequently initiating phosphorylation cascades inside the cell. Both 
epidermal growth factor (EGF) and transforming growth factor beta (TGF-P) are among 
the exogenous growth factors known to be expressed by tumors (Rooprai et al., 2000). 
Transforming growth factor beta (TGF-P) plays a vital role in tumorigenesis, 
acting as a key determinant of carcinoma cell behavior (Derynck et al., 2001). The TGF­
p Ras signaling pathway is complex in that it is both a tumor suppressor pathway and a 
promoter pathway of tumor progression and invasion. In regards to tumor progression, 
TGF-P l has been known to stimulate extracellular matrix protein synthesis and the 
chemoattraction of fibroblasts, resulting in a micro-environment that promotes tumor 
growth (Derynck et al., 200 I). In addition to promoting tumor growth, TGF-P I catalyzes 
migration and invasiveness of gliomas (Merzak et al., 1994). Coinciding research has 
also shown an inverse correlation between TGF-Pl expression in human gliomas and 
survival rate (Merzak et al. 1994). In regards to MMP-2, TGF-P has been shown to 
stimulate the transcription of proMMP-2 (Overall et al., 1989). 
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proMMP-2 active MMP-2 
TGF-Beta
-­---­.. 
TGF-Beta receptors 
Figure 1: Transforming growth factor-beta (TGF-P) signaling pathway. 
TGF-P binds to TGF-P receptors on the glioma cell surface, activating a Ras 
signal transduction pathway which stimulate tran cription of proMMP-2. The 
cleavage complex formed by two MTl-MMP molecules and one TIMP-2 
molecule then converts proMMP-2 into active MMP-2. 
Epidermal growth factor (EGF) also regulates many ignal-dependent pathways in 
tumors, and specifically stimulates tyrosine kinase ca cades. When treated with EGF, 
tumor pheroids from the human glioma cell line GaMG show increased growth cell 
shedding and tumor ceJI migration (Lund-Johan en et al., 1992). One study howed an 
antagonistic relationship between sequential radiation and admini tration of 1 3-bis 2-
chloroethyl)-1-nitrosourea (BCNU) chemotherapy in three primary human glioblastoma 
cell lines (Chakravarti et al., 2002). These cell lines demon trated strong expres ion of 
EGF, and in the presence of an EGF inhibitor cro s-re i tance between radiation and 
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chemotherapy was abrogated (Chakravarti et al., 2002). Thus, the epidermal growth 
factor receptor pathway may provide resistance to chemotherapy and radiation in 
gliomas. 
proMMP-2 active MMP-2 
EGF 
EGF receptors 
Figure 2: Epidermal growth factor (EGF) signaling pathway. EGF binds to 
EGF receptors on the U87MG gliorna cell surface, activating a signal 
transduction pathway which stimulates tyrosine kinase cascades. 
Phosphorylation of the tyrosine residue on the cytoplasmic tail of MTl-MMP 
may affect the MTI-MMP-dependent activation ofMMP-2. 
The relationship between the tyrosine phosphorylation of MTl-MMP's 
cytoplasmic tail and activity of MMP-2 is studied in this project using the U87MG p53 
wild type and T98G p53 mutant cell lines derived from human glioblastoma multiforme. 
U87MG cells are homozygous for the p53 genotype and express p53 proteins with wild 
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type transactivation activities (Van Meir et al., 1994). Wild type p53 promotes cell cycle 
arrest. The World Health Organization defines high-grade gliomas as the result of serial 
accumulations of genetic alterations which inactivate tumor suppressor genes such as p53 
(Furuta et al., 2004). One such glioma cell line, T98G, is homozygous for the p53 
genotype and is mutant at codon 237 (an alteration from ATG to ATA). This point 
mutation causes the replacement of the normal amino acid methionine with isoleucine 
(Van Meir et al., 1994). The MMP-2 gene contains a p53 binding site at its promoter 
(Bian and Sun, 1997). 
In this project, both U87MG and T98G cells are treated with TGF-P and 
subsequently analyzed for MMP-2 levels as well as concentration of MTl-MMP and 
corresponding phosphorylation of tyrosine. Additionally, the experiment is repeated with 
EGF using only U87MG cells. It is expected that treatment with TGF-P or EGF wiU 
upregulate MTl-MMP and P-Tyr in both U87MG and T98G cell lines. Furthermore, it is 
expected that an increase in the concentration of MTI-MMP as well as its 
phosphorylation will coincide with an increase in MMP-2 activity in 087 cells. Because 
T98G cells are mutant for p53, it is expected that upregulation ofMTI-MMP and P-Tyr 
will not produce a drastic increase in proMMP-2 or active MMP-2 levels. 
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Materials and Methods 
U87 and T98 mutant cell lines of human glioblastoma multiforme were used to 
investigate the relationship between activity of MMP-2 and the concentration of MTl­
MMP as well as phosphorylation of tyrosine via several procedures: passing cell , 
treating cells, immunoprecipitation, gel electrophoresis, Bradford Assay, Western Blot 
and chemiluminescence. 
Passing Cells 
Initially, one T25 flask was inoculated with 300,000 cells and then split in order 
to obtain the maximum number of viable cells. To split the cells phosphate buffered 
saline (PBS: 8%NaCI, 1. 15% Na2HPO4, 0.2% KCl, 0.2%KH2PO4), Dulbecco's Modified 
Eagle Medium (DMEM: 500mL DMEM, 5mL NEAA, 5mL PenStrep, 0.5ml 
Gentamycin SQ4) with fetal bovine serum (FBS: 50mL) and DMEM without FBS were 
warmed in a 37° C water bath. Frozen I OX Trypsin EDTA was heated in the water bath 
until thawed and then inverted a few times and kept on ice. Trypsin for washing the cells 
was made with 1.25mL I OX Trypsin EDTA and 3.75ml DMEM without FBS for a T25 
flask (3.75mL IOX Trypsin EDTA and l l .25m.L DMEM without FB for a T75 flask). 
Media was removed from the cells and cells were washed with 6mL PB for a 
T25 flask (18.0mL for a T75). PBS was transferred to a waste beaker and celJs were then 
washed with 4m.L of prepared Trypsin for a T25 flask (12.0mL for a T75). Cell were 
incubated for at least 3 minutes and then looked at under a microscope to ensure cells 
were floating. The flask was bit sharply on the side when necessary to dislodge the cells. 
9mL of DMEM with FBS were added to the flask to stop the action of the Trypsin in a 
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25. flask (27.0mL for a T75). The contents of the flask were transferred to a 50mL
onical tube and centrifuged for ten minutes at 1,300 rpm at room temperature. The 
upematant was removed and 1.0mL DMEM with FBS was added to resuspend the pellet 
or the pellet was resuspended in lmL ofDMEM with FBS five times, culminating in a 
otal volume of 5mL for the resuspended pellet). A cell count was performed using a 
emacytometer and the appropriate number of cells was aliquoted into T25 flasks 
ontaining 5mL DMEM with FBS for treatment or into a T25 or T75 flask (the latter 
containing l 5mL media) for maintenance of a stock. 
reating Cells 
When cells reached 90-95% confluency, they were treat�d with TGF-P (US 
iological T8250- 15A). DMEM without FBS and PBS were warmed in a 37° C water 
ath. Media was removed from the cells of two T25 flasks, and cells were rinsed with 
mL PBS. The PBS was removed from the flask and then 5mL DMEM without FBS was 
dded to each flask. To the treatment flask, IOµl of a 5ng/µl sample of TGB-P ( l µI 
GF-P freshly diluted in 9µ1 Bovine Serum Albumin-PBS solution) was added. Both 
asks were incubated for forty-eight hours. 
mmunoprecipitation 
Lyse cells with PfS 
Nutate supernatant with washed agarose 
xg 
Nutate supernatant with MT1-MMP antibody overnight 
xg 
Nutate lysate with washed agarose 
xg 
Wash pellets 
xg 11 
Cells were immunoprecipitated after forty-eight hours of incubation following 
treatment. 6mL of protease inhibitor solution (PIS per mL: 833µ1 PBS, 147µ1 50mM 
n-octyl glucopyranoside [Sigma 0-9882], 10µ1 1 µg/mL aprotinin [Sigma A-6279], 5µ1
lmM phenylmethylsulfonyl fluoride [PMSF; Sigma P-7626], 2µ1 1 µg/mL Pepstatin A
[Sigma P-5318], 1µ1 l mM CaCh, 1µ1 l mM MgCh, 1µ1 lµg/mL leupeptin) was made up 
for the treated and untreated T25 flasks. All conditioned media was removed from each 
T25 flask and frozen for later use in the zymogram. The cells were rinsed with 6mL of 
warm PBS three times. After the third rinse the PBS was drained for two to four minutes 
(with the flasks standing on end) and all additional liquid was pipetted off. 2mL of PIS 
was pipetted into each flask to lyse the cells, and the flasks were placed on ice gently 
rocking for one hour ( ensuring the flasks were flat so that the PIS completely covered the 
cells). After an hour, the liquid was pulled out of the +TGF-f3 flask and put into two 
microcentrifuge tubes (approx. 1 mL per tube). The same was done for the -TGF-f3 flask. 
Tubes were spun down for fifteen minutes at 14,000 rpm at 4° C. While the tubes were 
spinning, washed agarose was prepared. 150µ1 of agarose (Calbiochem JP06) from the 
stock tube was put into a new microfuge tube. 1,500µ1 of PIS was added to the tuoe and 
the tube was lightly vortexed. The tube was then spun down for one minute, and the 
supernatant was removed and discarded. The agarose pellet was resuspended in 150µ1 of 
PIS. 
For irrununoprecipitation procedure A: 
Two samples per treatment were simultaneously prepared in order to run 
duplicate gels after immunoprecipitation. 
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When the lysates stopped spinning, the supematants from each condition were 
removed and the preclear pellet was frozen. 30µ1 of washed agarose was combined with 
each sample tube (2 separate tubes for +TGF-13 with approximately l mL of sample in 
each; 2 separate tubes for -TGF-13 with approximately 1 mL of sample in each). All four 
tubes were left to nutate at 4 °C for two hours. After two hours, tubes were spun down at 
14,000 rpm for fifteen minutes at 4°C. An aliquot of the supernatant was saved on ice for 
a sessment of protein concentration using a Bradford Assay. The remaining precleared 
lysate (the supernatant) was saved for the gel (one tube per treatment) and stored at 4°C. 
Two tubes with 50µ1 of supernatant and 3 µI of MTl-MMP antibody ( 1 µg/µI; Chern icon 
International, AB815) per treatment condition were nutated overnight at 4°C. A 
Bradford Assay was performed at this point. 
For immunoprecipitation procedure B: 
One larger sample per treatment was prepared by immunoprecipitation to run one 
gel to be blotted, stripped and reblotted. 
When the lysates stopped spinning, the supernatants from the two treated tubes 
were combined in one sterile, round-bottom tube and the supematants from the two 
untreated tubes were combined in one sterile round-bottom tube· preclear pellets were 
frozen. 60µ1 of washed agarose was combined with the supernatant, and both tubes were 
placed in the nutator at 4°C for two hours. The contents of the round-bottom tube were 
transferred to microcentrifuge tubes to be spun down at 14,000 rpm for fifteen minutes at 
4 °C. An aliquot of the supernatant was saved on ice for assessment of protein 
concentration using a Bradford Assay. The remaining precleared lysate (the supernatant) 
was saved for the gel (one tube per treatment) and stored at 4°C. 100µ1 of supernatant 
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with 6µ1 of MTl-MMP antibody (lµg/µl) per treatment condition were nutated overnight 
at 4°C. A Bradford Assay was performed at this point. 
For the second day of immunoprecipitation procedure A, 30µ1 of washed agarose 
was added to each tube which had nutated overnight, and tubes then nutated at room 
temperature for two hours. For the second day of immunoprecipitation procedure B, 60µ1 
of washed agarose was added to each tube which had nutated overnight, and tubes then 
nutated at room temperature for two hours. 
For both procedures, all tubes were then centrifuged at 10,000 rpm for fifteen 
minutes at 4°C. The resulting supernatant was the no MTl condition saved at -20°C. 24 
ml of wash solution were prepared (5ml stock solution [0.5M NaCl and 50mM Tris-HCI 
in superwater, pH 7.4] + 2.5µ1 Tween-20 [Sigma P-7949]). The pellets were washed six 
times with 1ml wash solution per wash. They were centrifuged at 10,000 rpm for five 
minutes at 4°C between each wash. 
Gel Electrophoresis 
Samples were then prepared to run on a gel. Initially, duplicate gels were run but 
modifications in procedure Jed to one gel being run with stripping in between blotting. 
Further modifications led to loading 1 0µl of sample instead of 20µ1 of sample ( and thus 
reducing sample buffer and reducing agent by one half) due to bleeding of gel lanes. 
Later on, only IP-MTl samples were loaded (freezing preclear and no MTl samples for 
later use). In the later gels, for the no MTl and preclear lanes that were loaded, 1 0µl 
sample, 3µ1 4x sample buffer (Invitrogen NP0007) and 1.3µ1 reducing agent (Invitrogen 
NP0004) were combined. For the standard See Blue plus 2, I 0µl tandard (Invitrogen 
LC5925), 3µ1 4x sample buffer and 1.3µ1 reducing agent were combined. The earlier 
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method of preparing the gel used double these amounts (20µ1 sample, 10µ1 standard 
+ 10µ1 superwater). For the washed pellet (MTI condition), 20µ1 (immunoprecipitation 
procedure A) or 40µ1 (immunoprecipitation procedure B) of 2x sample buffer was added 
and the solution was incubated in a heating block (submerged in water) at 90°C for five 
minutes. The tube was then centrifuged for two minutes and 10µ1 of the sample was 
prepared by adding 3µ1 of 2X sample buffer and 1.3µ1 of reducing agent to run on a gel. 
Remaining MTl supernatant was frozen at -20°C. All gel samples, including the 
standard, were then incubated in a heating block (submerged in water) for ten minutes at 
10°c. 
For the 4-12% Bis-Tris gel (Invitrogen NP032 l ), 1,000mL of running buffer 
(lnvitrogen NP0002) for the outside chamber was made up using 50mL running buffer 
and 950mL superwater. 200mL of this solution was aliquoted out for the inner chamber 
of the gel with 500µ1 NuPage Antioxidant (Invitrogen NP0005) added. 
The gel was run at 200 volts for 35 minutes with lanes typically loaded in the 
following manner when preclear and no MTl samples were run in addition to MTl 
samples: 
I I preclear I 
-TGF-B I 
no MTI I IP-MTl I I 
+TGF-B I I preclear I no MTl I TP-MT1 I
When only MTl samples were used, samples were typically loaded in the 
following manner: 
[ std 
,
-TGF-B IIP-MTl I +TGF-B IIP-MTI
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After 35 minutes, the gel was transferred to nitrocellulose at 30 volts for one hour 
in IX NuPage transfer buffer (Invitrogen NP0006-l ). The top left comer of the 
nitrocellulose was cut for orientation purposes, and the nitrocellulose was left to dry 
overnight. 
Bradford Assay 
For both immunoprecipitation procedures A and B, a Bradford Assay was 
performed on the precleared lysate aliquots to identify protein concentrations. For 
protein concentration assessment, test tubes were typically prepared as indicated below, 
with two sample test tubes made up for each treatment condition: 
Blank: 3mL Bradford Coomasie Protein Reagent (Pierce 1856209), 100µ1 
superwater 
Sample: 3mL Bradford Coomasie Protein Reagent, 75µ1 sample, 25µ1 superwater 
Blank and samples were inverted to mix and then incubated for ten minutes at room 
temperature. The spectrophotometer was set at 595nm and zeroed with the blank. 
bsorbance values were recorded, and an average absorbance value for each treatment 
condition was calculated. 
Western Blot 
For each immunoprecipitation procedure, both MTI-MMP and phosphotyrosine 
(P-Tyr) blots were performed. 
To begin the Western blot, IOX tris-buffered saline (TBS: 1.54 NaCl and 0.I0M 
Tris-HCI pH 7.4) was made. Then it was diluted 1 :10 for use in the Western blot. IOmL 
IX TBS+ 0.3g milk powder were thoroughly mixed per each nitrocellulose paper. The 
nitrocellulose was rehydrated in superwater and rolled protein-side-in into a bottle. The 
TBS/milk powder solution was poured into the bottle and the bottle with the 
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nitrocellulose blocked for sixty minutes. The solution was removed and replaced with 
'IOmL Ix Tl3S and rotated for ten minutes. During this time, lOOmL TBS-T (99.8mL Ix 
TBS + 0.2g tnilk powder+ 200µ1 Tween-20) was made up per blot. The TBS was 
poured off the nitrocellulose and replaced with 7.5mL TBS-T along with 1.5µ1 rabbit 
anti-MTI-MMP primary antibody ( 1  mg/ml; Chemicon International, AB815) for MTl­
MMP blots or 1 µl phosphotyrosine primary antibody (7mg/ml; Chemicon International 
AB 1599) fot P-Tyr blots. The nitrocellulose was rotated for sixty minutes at room 
temperature. The TBS-T-antibody mix was poured off and replaced with IOmL TBS-T 
rotating for 10 minutes. The TBS-T wash step was repeated twice more. 7.5mL TBS-T 
and 1.5µ1 goat anti-rabbit secondary antibody (200µg in 0.5ml; Santa Cruz, SC-2004) 
were added and the nitrocellulose was rotated for 60 minutes. The TBS-T-antibody mix 
was poured off and the blot was washed with l OmL TBS-T for five minutes. This step 
was repeated three more times and was immediately followed by chemiluminescence. 
Chemiluminescence 
To ptepare for chemiluminescence, first 7mL of 1:1 mixture of enhanced 
chemiluminescence (ECL [Amersham Biosciences RPN2209]: 3.5mL reagent 1 + 3.5mL 
reagent 2) rehydrated the nitrocellulose blot for approximately one minute. ECL reagents 
were drained from the nitroceUulose onto a paper towel, and the nitrocellulose was 
wrapped in saran wrap. The nitrocellulose was taped down in an x-ray tray, and a piece 
of film was cut to match the nitrocellulose. The tray was closed and the film was 
exposed for one minute (exposure time was adjusted as needed). After exposure, the film 
was placed into the developer for one minute. Then the film was transferred to the stop 
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bath for apptoximately three minutes with slight agitation. Finally, the film was 
transferred to the fixer for at least thirty seconds of constant agitation. 
Stripping a Blot 
The blot was rehydrated in superwater and then stripped for 20 minutes using 
I0mL Pierce's Restore Western Blot Stripping Buffer at 37°C. The blot was then washed 
with I 0mL of IX TBS for ten minutes at room temperature and then washed again with 
I0mL of IX TBS for five minutes. Blot was stored at 4°C in TBS-T until another 
Western was repeated. 
Altei-hatively, the blot was rehydrated in superwater and stripped for fifteen 
minutes at room temperature using 20rnL of IX Antibody Stripping Solution (Chernicon 
0513). Stripping was then followed by two five minute washes with blocking solution 
(same as blocking solution used in the Western). Blot was stored at 4°C in TBS-T until 
another Wes tern was repeated. 
Zymography 
Zyitiography was also performed using the conditioned media saved at the 
beginning of the immunoprecipitation. To start, 15µ1 of the conditioned media was 
mixed with 15µ1 2X Tris-glycine SDS sample buffer (Invitrogen LC2676) and a 1: 100 
dilution ofGelatinase Zymography Standard (Chemicon CC073) was prepared using the 
2X Tris-glycine SDS sample buffer. All samples were incubated for ten minutes at room 
temperature. While the mixture was incubating, the gel apparatus was set up using a 10% 
zymogram gel (Inyitrogen EC6175BOX) in IX DS running buffer (Invitrogen LC2675-
5). After loading the gel with the conditioned media and 8µ1 of the diluted standard, the 
gel was ruh at 120 volts for 90 minutes at room temperature. 1 Ox renaturing buffer 
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.. 
(Invitrogeri LC2670) was used to wash the gel at room temperature with agitation for 
thirty minutes. After thirty minutes the gel was put in IX developing buffer (Invitrogen 
LC2671) at 37°C overnight. The gel was then stained using 0.5% Coomassie Blue Stain 
(25% isoptopanol, 10% glacial acetic acid, superwater, Brilliant Blue R [Sigma B-0149]) 
for at least one hour and fifteen minutes with agitation and then removed and destained 
with agitation for three hours with destaining solution (10% isopropanol, 10% HOAc, 
80% superwater). 
19 
Incubate without growth factor 
I 
Conditioned Media 
Zymogram for MMP-2 
activity 
U87 or T98 cells 
Incubate with TGF-Beta or EGF 
48 Hours 
Cell Lysate 
Immunoprecipitate with MTl­
MMP antibody 
Western Blot for MTl-MMP 
and Phosphotyrosine 
Figure 3: Flow chart detailing methods. Sequence of treatment, imrnunoprecipitation 
and western blot anal sis of U87 and T98 cells. 
Results 
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Treatment with Transforming Growth Factor Beta (TGF-fJ) 
U87 and T98 cells were treated with I Ong/ml ofTGF-�. Following treatment, 
conditioned media was saved for zymography to assess MMP-2 activity. Cells were 
lysed using a protease inhibitor solution and the lysate was then incubated with agarose to 
clear it of rtonspecifically-binding proteins. The subsequent precleared lysate was u ed 
for immunoprecipitation with MTl -MMP primary antibody. 
After treating U87 cells with TGF-�, western blot analysis of two 
immunoprecipitation experiments shows le s MTl-MMP in the treated condition as 
compared to the untreated (Figure 4). Although a Bradford As ay indicates that the 
untreated sample had almost double the protein concentration of the treated sample, 
densitometry data indicates at least a three-fold difference in band strength, confirming 
that the untreated sample has a greater concentration of MTl-MMP (Table 1 and Figure 
4). The percent change of treated to untreated sample is 46.9%, demonstrating more than 
a doubling ofMTl-MMP in the untreated sample as compared to the treated. 
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22 
treated untreated 
densitome 386,976.82 1 386,000.00 
0.025 0.042 
0.25 0.42 
1,547,908 3,300,000 
46.9 
Figure 4: Western blot for MTl-MMP in 087 cells. 
Immunoprecipitation followed by Western blot analysis 
using an MTl -MMP primary antibody reveaJs a greater 
concentration of MTl-MMP in the untreated sample. 
Western blot analysis for MTl-MMP on one other U87 immunoprecipitation did not 
confirm these results (Table I). Furthermore, protein concentrations for the experiment 
contradicting the above resuJts (Figure 4) were the highest of all irnmunoprecipitations 
performed in this research project (Table 1). Two U87 immunoprecipitations produced 
inconclusive results due to errors in the loading of the gel or lack of data on protein 
concentrations (Table I). 
Western blot analysis for phosphorylated tyrosine on several immunoprecipitation 
experiments using TGF-P-treated U87 cells is inconclusive (Table 1 ). Three out of four 
immunoprecipitations demonstrated a greater concentration of P-Tyr in the treated 
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condition with the average percent change at 223.2%. However, one 
imrnunoprecipitation produced contradictory results with a percent change of 69.3% 
(Table 1). 
For T98 cells treated with TGF-P, the general trend across immunoprecipitation 
experiments indicates less MTl-MMP protein in the treated condition as well as less 
phosphorylated tyrosine (Table 1; Figures 5 and 6). In one representative 
immunoprecipitation, although protein concentration in the untreated sample is less than 
the treated sample by 0.073µg/µl, densitometry of the bands sJightly under the 62kDa 
mark in the MTl sample lanes indicates that the untreated sample still has a ignificantly 
greater band intensity corresponding to MTI-MMP (Figure 5). The percent change of 
treated to untreated sample is 59.5%, demonstrating close to a doubling of MTl-MMP in 
the untreated sample as compared to the treated. 
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untreated treated 
204,344.13 157,214.92 
0.250 0.323 
2.50 3.23 
81,738 48,673 
59.5 
Figure 5: Western blot for MTl-MMP in T98 cells. 
Immunoprecipitation followed by Western blot analysis 
using an MTl-MMP primary antibody reveals a greater 
concentration ofMTl-MMP in the untreated sample. 
Three other immunoprecipitation experiments confinn this data, with an average 
percent change among the four experiments of 61.0% (Table 1). However, one T98 
immunoprecipitation showed contradictory results with a greater concentration ofMTl­
MMP in the treated sample (Table I). 
A Western for phosphorylated tyrosine using the same nitrocellulose as shown 
above (Figure 5) indicates less protein in the treated MTl sample lane (Figure 6). 
Densitometry indicates that the untreated MT l sample has almost double the band 
strength per microgram of protein loaded as compared to the treated sample with a 57.6% 
change (Figure 6). However data from three other immunoprecipitation experiments 
does not confirm this data, showing an average percent change of 103.1% (Table 1). 
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untreated treated 
densitometry 312,100.00 232,235.29 
concentration ( uir/µl) 0.250 0.323 
amount loaded (ug) 2.50 3.23 
densitometry/ug 124,840 71,899 
percent change - 57.6 
Figure 6: Western blot for P-Tyr in T98 cells. 
Following Western blot for MTl-MMP as shown in 
Figure 5, the nitrocellulose was stripped and rebJotted 
for phosphotyrosine. Blot shows greater band strength 
at 62kDa in the untreated sample. 
After treating with TGF-P and then completing five immunoprecipitation 
experiments on T98 cells (samples from two experiments were rerun on a gel) and four 
immunoprecipitation experiments on U87 cells (samples from one experiment were rerun 
on a gel), results were inconsistent (Table 1 ). In order to ensure equal amounts of protein 
across treatments two immunoprecipitation samples were blotted for actin. Results 
indicate that for these two immunoprecipitation experiments, equal protein in the 
untreated and treated lanes was loaded (Figure 7). 
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Figure 7: 087 and T98 cell line immunoprecipitation samples 
blotted for actin. In order to ensure that the same amount of 
protein was present in each sample so that comparative results were 
accurate, three immunoprecipitation samples were loaded on a gel 
and blotted for actin. Results indicate equal band strength across 
treatments within the T98 cell line, thus ensuring that differences in 
band strength observed for these experiments when blotted for MTl 
or P-Tyr are not due to a difference in overall protein concentration 
but rather to a difference in levels ofMTl or P-Tyr. 
Zymography on treated U87 and T98 conditioned media arnples was also inconclusive, 
and therefore the data was not included. 
Treatment with Epidermal Growth Factor (EGF) 
U87 cells were treated with 20ng and 80ng ofEGF. Following treatment 
conditioned media was saved for zymograpby to assess MMP-2 activit y. Cells were 
lysed using a protease inhibitor solution and the Iysate was then incubated with agaro e to 
clear it of nonspecifically-binding proteins. The subsequent precleared ly ate wa u ed 
for immunoprecipitation with MT1-MMP primary antibody. 
Subsequent Western blot analy is with MTl-MMP antibody reveals an increase in 
concentration in the treated Janes (Figure 8A). Although development of this blot i 
uneven, densitometry analysis subtracts the background and indicates that treatment with 
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EGF increases MTl-MMP concentration with 80ng EGF resulting in a 228.1% change a 
compared to the untreated condition. Western blot analy is of the ame 
irnmunoprecipitation using a phosphotyro ine antibody al o reveal an increase in 
concentration in the treated lanes (Figure 8B). 
MT1-MMP Phosphotyrosine 
Std -EGF +20ng +80ng Std -EGF + 20ng +80ng 
62 kDa- 62 kDa-
A 
MTl-MMP P-Tvr
-EGF +20ng +80ng -EGF +20ng +80ng
densitometry 64,927.96 70,672.07 118,465.15 39,589.27 43,955.24 52,776.06 
concentration 
(µQ/µJ) 0.150 0.160 0.120 0.150 0.160 0.120 
amount 
loaded (µg) 3.00 3.20 2.40 3.00 3.20 2.40 
densitometry I
U!! 21,642 22,085 49,360 13,196 13,736 21,990 
percent 
change - 102.1 228.1 - 104.1 166.6 
Figure 8: Treatment ofU87 cells with epidermal growth factor. Comparison of MT1-
MMP in untreated cells (-EGF) and cells treated with 20ng EGF (+20ng) and 80ng EGF 
(+80ng). Western blot (A) monitors the presence of MTl-MMP using an MTI-MMP 
primary antibody. Western blot (B) monitors the presence of phosphorylated MTl-MMP at 
the tyrosine phosphorylation site using a phosphotyrosine primary antibody. An anti-rabbit 
secondary antibody was used for both blots. Each Western blot was preceded by an 
immunoprecipitation that yielded an MTI sample for each condition. ee Blue Plus 2 
standard was used on both gels, but the MT1-MMP antibody does not recognize the 
proteins in the standard. Both blots show an increase in protein concentration in the 
treated lanes. 
Zymography on conditioned media from EGF-treated U87 cells howed no effect 
on levels of MMP-2 (Figure 9). Furthermore re ults indicate a slight conversion of 
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proMMP-2 (68kDa) into active MMP-2 (62kDa). The faint upper bands at 92kDa 
probably correspond to secreted MMP-9. 
M 
p 
A 
Std (-) +20 +80 (-) +20 +80 
Figure 9: Zymogram of conditioned media from U87 cells treated with epidermal 
growth factor. Comparison ofMMP-2 activity in untreated cells(-), cells treated with 
20ng EGF (+20), and cells treated with 80ng EGF (+80). The standard has thick bands 
due to MMP-9 (M) and MMP-2 (A). The two sets of bands are representative of two 
different sets of experiments. The zymography results show the inactive pro form (P) of 
the enzyme at 68kDa and a faint band representing the active form (A) which migrates 
ahead of the pro form at 62kDa. 
Discussion 
Data collected from immunoprecipitations of both U87 and T98 cells when 
treated with transforming growth factor beta is inconsistent. A generalized conclusion 
based on two U87 immunoprecipitations shows less MTl -MMP in the treated sample. 
This data fails to validate data produced last year (Cox, 2004). Additionally, data from 
these two experiments may not be reliable because absorbance values taken on the lysate 
are below 0.1 and thus protein concentrations were low. Data for P-Tyr using U87 
immunoprecipitation samples is also inconclusive, although the majority of experiments 
indicate a greater concentration of phosphorylated tyrosine in the treated condition. This 
majority data includes the immunoprecipitation with the highest protein concentration. 
However, this conclusion also fails to validate data produced last year (Cox, 2004). 
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Furthermore, immunoprecipitation samples producing the most reliable MTI-MMP data 
showed less P-Tyr in the treated condition which contradicts three other 
immunoprecipitations that demonstrated greater P-Tyr concentration in the treated 
condition. It should be noted that although the tyrosine on the cytoplasmic tail of MTl­
MMP is known to be phosphorylated, this research project does not include data that 
indicates that it is this tyrosine residue on the cytoplasmic tail which is phosphorylated. 
Contradictory results for both MTl-MMP and P-Tyr in U87 cells treated with 
transforming growth factor beta may be due to inadequate protein concentrations. For 
each immunoprecipitation done with U87 cells, at least one sample if not both the 
untreated and treated samples had an absorbance 595nm value ofless than 0.1 (Table 1 ). 
The general trend for T98 immunoprecipitations according to densitometry shows 
greater band strength in the untreated lanes for MTl-MMP and no effect on the 
phosphorylation of tyrosine with a percent change of 103.1 % when comparing treated 
samples to untreated samples. These findings imply that treatment with TGF-B in T98 
cells does not facilitate the production of MTl-MMP. 
The T98 p53 mutant cell line has an inactivated p53 tumor suppres or gene. The 
tumor suppressor protein, p53, acts as a transcription factor for the MMP-2 gene. 
Without this tumor suppressor protein transcription ofMMP-2 may be hindered. 
Because zymography data was inconclusive for both cell lines, a generalization about the 
connection between the phosphorylated state ofMTl-MMP and its activation cannot be 
made, nor about MTl-MMP's effect on the production ofMMP-2. However, one might 
expect that TGF-B would have a similar effect on MTl-MMP production and 
phosphorylation in both cell lines with treatment producing a change in MMP-2 levels in 
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U87 cells and little change in MMP-2 levels in T98 cells as transcription of MMP-2 is 
hampered. 
There were a number of potential reasons why the TGF-P immunoprecipitation 
results were inconclusive. Halfway through the semester, new TGF-� was ordered and 
aliquoted to ensure that the growth factor was still functional. Additionally, the 
procedure was modified from immunoprecipitation procedure A to immunoprecipitation 
procedure B as stated in the methods to ensure that immunoprecipitation samples were 
being treated identically. Furthermore, when possible, duplicate gels of 
immunoprecipitation samples were run in order to eliminate the loss of protein due to 
stripping in between blotting for MTI-MMP and for phosphorylated tyrosine. Especially 
for U87, protein concentrations across immunoprecipitation experiments were too low. 
An effort was made to allow the cells to become even more confluent before treating but 
this did not seem to improve the protein concentration. Originally, cells were treated 
with 1 Ong/ml TGF-� based on a previous concentration curve (Lewis, 2003). However, 
when results indicated little difference in band strength across treatments, another 
concentration curve was performed to verify the optimal concentration for treatment. 
This concentration curve treated U87 cells with 10ng/ml, 50ng/ml and IO0ng/ml ofTGF­
p and indicates that treatment with 100ng/ml as opposed to 10ng/ml may be most optimal 
for clear results. Additional immunoprecipitation experiments using l 00ng/ml TGF-P for 
treatment of cells would be appropriate. 
Finally, zymography results on U87 and T98 cells treated with transforming 
growth factor beta are inconclusive. Future experiments should ensure that a zymogram 
31 
is run on fresh conditioned media as zymograpby on refrozen samples was found to be 
ineffective due to the degradation of protein from thawing and refreezing. 
Treatment of U87 cells with epidermal growth factor correlated with an increase 
in MTl-MMP levels as well as an increase in phosphotyrosine levels. Percent change 
for MTI-MMP and P-Tyr were 102.1% and 104.1% respectively for 20ng EGF and 
228.1 % and 166.1 % respectively for 80ng EGF (Figure 8). This data indicates more than 
a doubling ofMTI-MMP with treatment of 80ng EGF and an almost 50% increase for P­
Tyr. The effect of EFG on MTl-MMP at 80ng appears to be greater than its effect on P­
Tyr. These conclusions are supported by duplicate experiments. The increase in MTI­
MMP implies that EGF may play a role in the activation of MTJ-MMP. However since 
EGF treatment did not affect the amount ofproMMP-2, the amount and phosphorylation 
state ofMTl-MMP have no observable effect on MMP-2 levels. The effect of the 
phosphorylation state ofMTl-MMP on the activation ofMMP-2 cannot be deduced 
because only a small portion of proMMP-2 in the conditioned media is converted to the 
active form irrespective of treatment with EGF. The active MMP-2 form migrates at 
62kDa, a slightly smaller size than the pro-form at 68kDa which is cleaved by the MTl­
MMP/TIMP-2 complex during activation. Although these results confirm one 
experiment (Lewis, 2003), they do not confirm the majority of past research which 
indicates that production and secretion of MMP-2 increases with increasing EGF 
concentrations (Rooprai et al, 2000; Uhm et al., 1997; Weed, 2004). Further re earch 
investigating the effects of epidermal growth factor might elucidate EGF's role in MMP-
2 production. Since past research indicates that TIMP-2 indirectly stimulates tyrosine 
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phosphorylation, it would be interesting to investigate TIMP-2 levels in EGF-treated U87 
cells. 
Results from this research project, although inconclusive for treatment with 
transforming growth factor beta, do indicate that EGF upregulates MT 1-MMP production 
as well as P-Tyr. Further research, including appropriate zymography results, must be 
performed before conclusions can be made regarding MTl -MMP's effect on the 
activation of MMP-2. 
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Treatment Densitometry (Net intensity)/µg Percent Change 
MT1- MT1-
MMP MMP P-TYR P-TYR MT1-MMP P-Tvr 
Cell - MT1-
Line -TGF +TGF TGF +TGF -TGF +TGF -TGF +TGF MMP P-Tvr 
U87 less more less more 101,839 233,126 290,029 504,076 228.90% 173.80% 
U87 gel gel less more - - 365,361 1,101,760 - 301.60%
U87 more less less more 3,300,000 1,547,908 645,893 1,255,176 46.90% 194.30%
U87 more less more less 372,108 225,723 318,296 220,446 60.70% 69.30%
U87 - - - - - - - - - -
T98 more less gel gel 149,259 57,845 -- - 38.80% -
T98 more less gel gel 302,629 199,240 - - 65.80% -
T98 more less gel gel 98,488 78,561 - - 79.80% -
T98 more less more less 81,738 48,673 124,840 71,899 59.50% 57.60% 
T98 gel gel even even - - 49,228 48,104 - 97.70% 
T98 gel gel even even - - 146,330 163,306 - 111.60% 
T98 less more even even 174,360 302,695 111,077 111,012 173.60% 99.90% 
Table 1: lmmunoprecipitation data from U87 and T98 samples treated with TGF-Jl. Values in 
parentheses indicate an absorbance 595nm value of less than 0.1. "Gel" indicates that results were 
inconclusive due to procedural problems. "Even'1 indicates that results were inconclusive because 
there was no significant difference in band strength. 
